Genscript Biotech pulls off $304m follow-on
Genscript Biotech Corp, a leading life sciences service provider and drug developer, has raised HK$2.39bn ($304m) after upsizing a follow-on offering, according to a source close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts